Purple Biotech Ltd
PPBT
$2.53
-$0.1193-4.50%
NASDAQ
| 12/31/2024 | 06/30/2024 | 12/31/2023 | 09/30/2023 | ||
|---|---|---|---|---|---|
| Net Income | 91.51% | 53.19% | 19.68% | -4.39% | |
| Total Depreciation and Amortization | -16.67% | -7.55% | -4.00% | 6.38% | |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | |
| Total Other Non-Cash Items | 49.13% | -254.64% | -605.22% | -158.22% | |
| Change in Net Operating Assets | -195.08% | -34.54% | -29.51% | 125.50% | |
| Cash from Operations | 59.57% | 23.88% | -18.22% | -0.97% | |
| Capital Expenditure | -- | -- | -- | 116.67% | |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | |
| Cash Acquisitions | -- | -- | -- | -- | |
| Divestitures | -- | -- | -- | -- | |
| Other Investing Activities | -48.65% | -56.28% | -99.07% | 449.18% | |
| Cash from Investing | -48.65% | -56.06% | -99.07% | 468.36% | |
| Total Debt Issued | -- | -- | -- | -- | |
| Total Debt Repaid | -14.29% | -9.52% | -2.44% | -2.44% | |
| Issuance of Common Stock | 109,075.00% | 16.05% | -97.85% | 2.88% | |
| Repurchase of Common Stock | -- | -- | -- | -- | |
| Issuance of Preferred Stock | -- | -- | -- | -- | |
| Repurchase of Preferred Stock | -- | -- | -- | -- | |
| Total Dividends Paid | -- | -- | -- | -- | |
| Other Financing Activities | -108.87% | -10.39% | 7,750.00% | -30.61% | |
| Cash from Financing | -7.23% | 17.98% | 4,670.79% | 0.53% | |
| Foreign Exchange rate Adjustments | -100.00% | 78.26% | -42.68% | 64.91% | |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | |
| Net Change in Cash | 419.19% | 26.06% | -115.55% | 28.44% | |